An Israeli startup that uses artificial intelligence to help manage treatment courses for diabetics has received a fifth clearance from the US Food and Drug Administration (FDA) for its endo.digital platform.
The new FDA clearance allows DreaMed to expand the scope of its recommended care plans for diabetics on a fixed regimen of insulin doses that are administered via pump or injection.
The endo.digital platform provides an automated total care plan for people with diabetes. The company says it is compatible with most devices used by diabetics to monitor their blood glucose levels and to administer insulin.
Keep reading at nocamels.com.
DreaMed Diabetes uses artificial intelligence to help manage treatment courses for diabetics. DreaMed Co-founder and Chief Medical R&D Officer Revital Nimri is a Technion alumna.
